Related Experiment Video
Updated: Aug 6, 2026

Mechanisms Underlying Gut Hormone Secretion Using the Isolated Perfused Rat Small Intestine
Published on: February 26, 2019
GLP-1 Receptor Agonists: From Clinical Success to Mechanistic Insight
Tapan A Patel1, Jill Rose1, Kenichi Katsurada2,3
1Department of Cellular and Integrative Physiology (T.A.P., J.R., P.K., J.S., K.P.P., M.A.), University of Nebraska Medical Center, Omaha.
Glucagon-like peptide-1 receptor (GLP-1R) agonists offer new hypertension and cardiometabolic syndrome treatments by targeting vascular-metabolic biology. They show promise for cardiovascular and heart failure outcomes, with research focusing on direct signaling and personalized therapies.
Area of Science:
- Cardiovascular Medicine
- Endocrinology
- Pharmacology
Background:
- Glucagon-like peptide-1 receptor (GLP-1R) agonists are revolutionizing cardiometabolic disease treatment.
- Current strategies focus on modifying underlying vascular-metabolic biology, not just risk factors.
Purpose of the Study:
- To review clinical advancements and mechanistic insights of GLP-1R agonists in hypertension and cardiometabolic syndrome.
- To identify translational gaps and future research priorities for optimizing therapy.
Main Methods:
- Integration of clinical trial data and experimental evidence on GLP-1R agonist effects.
- Analysis of mechanisms including endothelial function, inflammation, and cardiorenal pathways.
Main Results:
- GLP-1R agonists demonstrate benefits beyond weight loss and glycemic control, impacting vascular inflammation and plaque composition.
- Evidence suggests effects on cardiorenal pathways crucial for blood pressure regulation and heart failure.
Conclusions:
- Further research is needed to distinguish direct GLP-1R signaling from secondary effects and to identify patient response biomarkers.
- Personalized application and next-generation incretin-based therapies are key for durable vascular protection and blood pressure management.
More Related Videos
08:21Monitoring GPCR-β-arrestin1/2 Interactions in Real Time Living Systems to Accelerate Drug Discovery
Published on: June 28, 2019
07:41A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators
Published on: February 20, 2018
Related Concept Videos
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
G Protein-coupled Receptors
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
G-protein Coupled Receptors
GPCRs Regulate Adenylyl Cylase Activity
Two...
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
Drug-Receptor Interaction: Agonist
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous ligand's action.